Drug development is an intrinsically risky business. Like a high stakes poker game the entry costs are high and the probability of winning is low. Indeed, only a tiny percentage of lead compounds ever reach USFDA approval. At any point during the drug development process a prospective drug lead may be terminated owing to lack of efficacy, adverse effects, excessive toxicity, poor absorption or poor clearance. Unfortunately, the more promising a drug lead appears to be, the more costly it is to terminate its development. Typically, the cost of killing a drug grows exponentially as a drug lead moves further down the development pipeline. As a result there is considerable interest in developing either experimental or computational methods that can identify potentially problematic drug leads at the earliest stages in their development. One promising route is through the prediction or modeling of ADME (absorption, distribution, metabolism and excretion). ADME data, whether experimentally measured or computationally predicted, provide key insights into how a drug will ultimately be treated or accepted by the body. So while a drug lead may exhibit phenomenal efficacy in vitro, poor ADME results will almost invariably terminate its development. This review focuses on the use of ADME modeling to reduce late-stage attrition in drug discovery programmes. It also highlights what tools exist today for visualising and predicting ADME data, what tools need to be developed, and the importance of integrating ADME data to aid in compound selection during the earliest phases of drug discovery. It also discusses what kinds of tools need to be developed, and the importance of integrating ADME data to aid in compound selection during the earliest phases of drug discovery.
The steps involved in drug design, drug development and drug discovery are highly expensive, extremely challenging and time consuming. Although the drug designing, process has been hastened with the development of newer emerging techniques, and the fabrication of novel computational tool. Researchers are working on structure guided drug designing using a 3-D structure of target, the drug molecule identified by the use of target-based drug design shows great potential in preventing various diseases but also possess many side effects. In the rational drug design, structure-based designing, combinatorial drug designing and computer aided drug design techniques are employed. When gene expression and bioinformatics are incorporated with the combinatorial drug designing, that make the rational drug designing, a more powerful tool for drug discovery. The rational drug designing associated with gene expression and bioinformatical estimation is moderately emerging and expeditiously revamping the drug development with less time consuming, economic, effectiveness and cater novel combinatory therapy in addition to minimization of toxicity. This review discusses in detail about the fabrication of a successful drug candidate using multidisciplinary perspective of combinatorial chemistry with gene expression analysis, structure based and artificial intelligencebased drug designing. In future, more sophisticated computer-based methodologies would be required for developing new drug candidate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.